Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2, AZD6234 Formulation 3, AZD6234 solution for injection, AZD6234 Formulation 2 (high concentration), Lenbelintide
AZD6234 · 9 trials · 12 indications
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change from baseline of treatment.
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5% from baseline of treatment.
To evaluate the effect of AZD6234 as compared to placebo as an adjunct to incretin-based therapies in percent body weight change
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
To assess the safety and tolerability of repeated subcutaneous(SC) doses of AZD6234 compared to placebo.
To assess the safety and tolerability of repeated SC doses of AZD9550 and AZD6234 in combination with AZD9550 compared to placebo.
To determine whether treatment with AZD6234 is superior to placebo for weight loss at Study Week 26
To assess the effect of AZD6234 versus placebo on the proportion of participants with weight loss ≥ 5% from baseline at Study Week 26
To determine whether AZD6234 is superior to placebo for weight loss
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline
To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function
To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function
To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function
Area under plasma concentration-time curve from time zero to the last measurable concentration
Area under plasma concentration-time curve from zero to infinity
Maximum observed plasma concentration
| Arm | Type | Description |
|---|---|---|
| AZD6234 Higher Target-Dose | EXPERIMENTAL | Participants will receive AZD6234 with dose titration to the higher target dose, followed by a safety follow-up period. |
| AZD6234 Lower Target-Dose | EXPERIMENTAL | Participants will receive AZD6234 with dose titration to the lower target dose, followed by a safety follow-up period. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo with dose titration according to the protocol, followed by a safety follow-up period. |
| AZD6234 | EXPERIMENTAL | AZD6234 |
| AZD6234 Dose 1 | EXPERIMENTAL | AZD6234 Dose 1 |
| AZD6234 Dose 2 | EXPERIMENTAL | AZD6234 Dose 2 |
| AZD6234 (sub-study 1) | EXPERIMENTAL | Participants will receive subcutaneous injection of AZD6234 on Day 1 and continue for 16 weeks. |
| Placebo (sub-study 1) | PLACEBO_COMPARATOR | Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 16 weeks. |
| AZD9550(sub-study 2 Cohort A) | EXPERIMENTAL | Participants will receive subcutaneous injection of AZD9550 on Day 1 and continue for 28 weeks. |
| Placebo (sub-study 2 Cohort A) | PLACEBO_COMPARATOR | Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks. |
| AZD6234 in combination with AZD9550 (sub-study 2 Cohort B) | EXPERIMENTAL | Participants will receive subcutaneous injection of AZD6234 and AZD9550 on Day 1 and continue for 28 weeks. |
| Placebo (sub-study 2 Cohort B) | PLACEBO_COMPARATOR | Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks. |
| Placebo for AZD6234 | PLACEBO_COMPARATOR | Weekly SC injections of matching placebo |
| Arm 1 | EXPERIMENTAL | Dose 1 |
| Arm 2 | EXPERIMENTAL | Dose 2 |
| Arm 3 | EXPERIMENTAL | Dose 3 |
| Arm 4 | PLACEBO_COMPARATOR | Placebo - Dose matched with each Experimental arm |
| Group 1 | EXPERIMENTAL | Participants with severe hepatic impairment (CP Class C, score of 10 to 15). |
| Group 2 | EXPERIMENTAL | Participants with moderate hepatic impairment (CP Class B, score of 7 to 9). |
| Group 3 | EXPERIMENTAL | Participants with normal hepatic function matched on a group level regarding sex, age, and BMI to the participants with hepatic impairment. |
| Group 4 (optional) | EXPERIMENTAL | Subjects with moderate renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions |
| Group 5 (optional) | EXPERIMENTAL | Subjects with mild renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions |
| Name | Type | Description |
|---|---|---|
| AZD6234 | DRUG | administered once weekly. |
| Placebo | DRUG | Matching placebo administered once weekly. |
| Lenbelintide | DRUG | IMP injected subcutaneously, once a week. |
| AZD9550 | DRUG | Participants will receive a subcutaneous injection weekly |
| Plocebo | DRUG | Participants will receive a subcutaneous injection weekly |
| AZD6234 in combination with AZD9550 | DRUG | Participants will receive a subcutaneous injection weekly |
| Placebo to match | DRUG | Weekly SC injections of matching placebo |
| Placebo comparator | DRUG | Placebo matching IMP dose injected subcutaneously, once a week. |
Inclusion Criteria: * Aged 18 years or older at the time of signing informed consent. * Body mass index: * at least 28 kg/m²; or * at least 24 kg/m² and less than 28 kg/m² with at least one protocol-defined weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia,...
Top 20 of 37 competitors
AZD6234 is an investigational small molecule drug developed by AstraZeneca for metabolic conditions, including obesity, overweight, and related disorders. It is being studied in adults with obesity or overweight, including people who also have type 2 diabetes, and in participants with hepatic impairment. AZD6234 is not yet approved and remains in clinical development.
AZD6234 is being developed to manage weight in adults who are obese or overweight, including participants who may or may not also have type 2 diabetes. AstraZeneca is also studying it in people with overweight or obesity and type 2 diabetes who are on a stable dose of a GLP-1 receptor agonist.
AZD6234 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is running the clinical program for AZD6234 across obesity, overweight, hepatic impairment, and related metabolic indications, including studies in China, India, and the United States.
AZD6234 is in Phase 2 development overall, with a Phase 3 trial also registered. The Phase 3 study in obesity and overweight is not yet recruiting, while Phase 2 studies include a completed trial in overweight or obesity with type 2 diabetes and an active platform study in Chinese participants. AZD6234 is investigational and not approved.
AZD6234 trials include NCT06851858, a completed Phase 2 study in overweight or obesity with type 2 diabetes on a stable GLP-1 receptor agonist dose; NCT07017179, an active Phase 2 platform study in Chinese participants with obesity or overweight; NCT07546760, a recruiting Phase 1 hepatic impairment study; and NCT07922330, a Phase 3 weight management study not yet recruiting.
Yes. AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2, AZD6234 Formulation 3, and AZD6234 solution for injection all refer to the same investigational drug, AZD6234, developed by AstraZeneca. These names describe different formulations or presentations of the compound studied in its clinical program.